France – Médicaments divers – Fourniture de médicaments radiopharmaceutiques
AI summary
This tender concerns the supply of radiopharmaceutical medications, specifically a fluorine-based tracer targeting prostate-specific membrane antigen (PSMA). The product is used for initial staging of patients with high-risk prostate cancer before curative treatment and for detecting prostate cancer recurrence in patients with elevated PSA levels post-treatment.
Pharmaceutical companies specializing in radiopharmaceuticals or nuclear medicine imaging agents, with authorization to distribute medical isotopes and oncology tracers in France.
Suppliers must provide radiopharmaceutical products meeting clinical and regulatory standards for oncology imaging. Documentation of product certification, safety protocols, and compliance with pharmaceutical regulations is required.
Frequently asked questions
What is this tender about?
This tender concerns the supply of radiopharmaceutical medications, specifically a fluorine-based tracer targeting prostate-specific membrane antigen (PSMA). The product is used for initial staging of patients with high-risk prostate cancer before curative treatment and for detecting prostate cancer recurrence in patients with elevated PSA levels post-treatment.
What are the requirements for suppliers?
Suppliers must provide radiopharmaceutical products meeting clinical and regulatory standards for oncology imaging. Documentation of product certification, safety protocols, and compliance with pharmaceutical regulations is required.
What type of company should bid?
Pharmaceutical companies specializing in radiopharmaceuticals or nuclear medicine imaging agents, with authorization to distribute medical isotopes and oncology tracers in France.
Who is the buyer?
The buyer is Centre Hospitalier Alpes Léman (établissement support du GHT Léman Mont-Blanc).
When does this tender close?
Submissions close on June 10, 2026.
Fourniture de médicaments radiopharmaceutiques Traceur fluoré spécifique de l'antigène membranaire spécifique de la prostate permettant la stadification initiale des patients présentant un cancer prostatique à haut risque avant un traitement initial à visée curative ET la localisation de récidive du cancer de la prostate, chez les patients présentant une suspicion de récidive basée sur l’augmentation des concentrations sériques d’antigène prostatique spécifique (PSA) après un traitement initial à visée curative
Fourniture de médicaments radiopharmaceutiques
Fourniture de médicaments radiopharmaceutiques Traceur fluoré spécifique de l'antigène membranaire spécifique de la prostate permettant la stadification initiale des patients présentant un cancer prostatique à haut risque avant un traitement initial à visée curative ET la localisation de récidive du cancer de la prostate, chez les patients présentant une suspicion de récidive basée sur l’augmentation des concentrations sériques d’antigène prostatique spécifique (PSA) après un traitement initial à visée curative
Scoring criteria not specified
Computing match…
AI document analysis
We read the tender PDFs and DOCX files and surface key requirements, deadlines, budget and red flags.
Loading…